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Background: The Autotransporter pathway, ubiquitous in Gram-negative bacteria, allows the efficient secretion of
large passenger proteins via a relatively simple mechanism. Capitalizing on its crystal structure, we have engineered
the Escherichia coli autotransporter Hemoglobin protease (Hbp) into a versatile platform for secretion and surface
display of multiple heterologous proteins in one carrier molecule.
Results: As proof-of-concept, we demonstrate efficient secretion and high-density display of the sizeable
Mycobacterium tuberculosis antigens ESAT6, Ag85B and Rv2660c in E. coli simultaneously. Furthermore, we
show stable multivalent display of these antigens in an attenuated Salmonella Typhimurium strain upon
chromosomal integration. To emphasize the versatility of the Hbp platform, we also demonstrate efficient
expression of multiple sizeable antigenic fragments from Chlamydia trachomatis and the influenza A virus at
the Salmonella cell surface.
Conclusions: The successful efficient cell surface display of multiple antigens from various pathogenic organisms
highlights the potential of Hbp as a universal platform for the development of multivalent recombinant bacterial
vector vaccines.
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Live attenuated strains of pathogenic bacteria that synthesize
heterologous antigens are being developed as vaccines for
several infectious diseases and cancer. Attenuated derivatives
of Salmonella enterica serovar Typhimurium, a facultative
intracellular bacterium capable of provoking strong mucosal
and systemic cellular immune responses, have been most
extensively studied for this purpose [1]. Using Salmonella
vaccine strains, cell surface display or secretion of heterol-
ogous antigens has been shown to yield superior immune
responses compared to intracellular expression [2,3]. Un-
fortunately, in Salmonella and other Gram-negative bac-
teria like Escherichia coli, efficient secretion and surface* Correspondence: w.s.p.jong@vu.nl; s.luirink@vu.nl
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unless otherwise stated.display of heterologous antigens is difficult. This is due to
the presence of a complex, multi-layered envelope that
consists of two membranes (inner and outer) separated
by the periplasm that comprises a mesh-like peptido-
glycan layer.
The Autotransporter pathway [4,5], also known as the
Type Va secretion system [6], represents a ubiquitous
and simple mechanism for protein translocation across
the Gram-negative cell envelope and is typically used for
the secretion of large virulence factors. Autotransporters
are organized in three domains [7]: (i) an N-terminal sig-
nal peptide that targets the protein to the Sec translocon
for translocation across the inner membrane, (ii) a se-
creted passenger domain that carries the effector function,
and (iii) a C-terminal β-domain that integrates into the
outer membrane (OM) and facilitates translocation of the
passenger from the periplasm into the extracellular spaced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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β-barrel assembly machinery (Bam) complex [8,9]. The
Autotransporter system has been used for extracellular
expression of antigens, mostly upon direct fusion of heter-
ologous sequences to the β-domain [10]. Although yield-
ing promising results [4,10,11], in the context of vaccine
strains like attenuated Salmonella these attempts only
concerned single antigens or multiple small epitopes.
Moreover, reported expression and secretion efficiencies
were often low or difficult to evaluate [12-24].
Making use of the crystal structure of its secreted
passenger domain [25], we have recently engineered
the E. coli autotransporter Hemoglobin protease (Hbp)
into an efficient platform for the secretion and display of
heterologous proteins [15]. The structure features a long
(~100 Å) β-helical stem (β-stem) that appears to function
as a stable scaffold for five protruding side domains
(d1-d5) (Figure 1; Additional file 1: Figure S1) [25]. Whereas
the basic β-stem structure is well conserved among auto-
transporters and has been implicated in autotransporter
biogenesis and transport [26], the passenger side domains
are dispensable for secretion of Hbp and can be replaced
by the Mycobacterium tuberculosis antigen ESAT6. Using
this strategy, ESAT6 was efficiently transported to the
extracellular environment (surface display or secretion) of
E. coli and attenuated S. Typhimurium [15].Figure 1 Strategy for Hbp-mediated secretion and display of
heterologous antigens. Schematic representation of the secretion
and display strategy based on the Hbp passenger and β-domain
crystal structures [25,27]. Heterologous antigens x, y, and z are fused
to the Hbp passenger domain, individually or simultaneously, by
(partially) replacing any of the side domains d1 (red), d2 (green), d3
(yellow), d4 (magenta) or d5 (orange). Scissors indicate a cleavage site
between the passenger and β-domain, which was left intact (+) for
secretion purposes and disrupted (−) for surface display. The image
was created using MacPyMol.Here, we present a systematic analysis to explore whether
Hbp can be used as a platform for simultaneous display
or secretion of multiple antigenic proteins (Figure 1) to
enable the production of multivalent vaccines. As proof of
concept, we demonstrate efficient secretion and high-
density display of the well-known Mycobacterium tubercu-
losis antigens and vaccine targets ESAT6, Ag85B and
Rv2660c [28] incorporated in one Hbp molecule, both in
E. coli and an attenuated S. Typhimurium vaccine strain.
Using Hbp as a carrier we also achieved efficient surface
exposure of antigenic fragments from the Chlamydia tra-
chomatis major outer membrane protein (MOMP) as well
as sizeable conserved domains and epitopes from the in-
fluenza A virus. These data underline the potential of Hbp
as a versatile carrier for high-density surface display of an-
tigens to produce multivalent bacterial live vaccines. It is
important to note that this seminal live platform has
guided the development of two derived non-living plat-
forms, outer membrane vesicles [29] and bacterial ghosts
(De Gier et al., submitted), which can both be decorated
with the same Hbp fusion proteins and are considered
very safe alternatives for live bacterial vector vaccines
[30,31]. The common basis of the three platforms enables
the rapid development of vaccine candidates that are tai-
lored to specific requirements.
Results
Secretion of the split mycobacterial antigen Ag85B
We have previously shown that the Hbp passenger side
domains d1–d5 are dispensable for secretion of Hbp and
can be replaced by a small flexible spacer of alternating
glycine and serine residues. Furthermore, insertion of
the well-known 9.9 kDa M. tuberculosis antigen ESAT6
[32] into these linkers to replace any of the side domains
d1–d5 resulted in successful secretion of the antigen
into the extracellular space [15].
ESAT6 folds into an α-helical hairpin [33], a relatively
simple structure that was previously shown to be compat-
ible with Hbp-mediated translocation [9]. To analyze the
tolerance of the Hbp system towards more complex anti-
gens, we analyzed the secretion of the Ag85B protein, a
secretory 31 kDa T-cell antigen from M. tuberculosis with
a globular structure containing one disulfide bond [34].
Hbp(Δd1)-Ag85B, carrying the Ag85B moiety at position
d1 of the Hbp passenger (Additional file 2: Figure S2),
was cloned under lacUV5-promoter control into vector
pEH3 and expressed in E. coli strain MC1061. Cells were
grown to early log-phase after which the expression of
Hbp was induced by the addition of isopropyl β-D-
thiogalactopyranoside (IPTG). Growth was continued and
2 h after induction samples were collected and centrifuged
to separate cells and spent medium. To monitor expression
and secretion of Hbp, both fractions were analyzed by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
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Figure S3A). Unfortunately, Ag85B fused to Hbp appeared
to be largely secretion incompetent (lane 5–6, Additional
file 3: Figure S3A) and degraded in the periplasm by the
protease DegP as evidenced by the vast accumulation of
non-processed 146 kDa Hbp-Ag85B pro-form material in
cells lacking a proteolytically active periplasmic protease
DegP (lane 11, Additional file 3: Figure S3A). The secre-
tion block was only marginally relieved by using a strain
that lacks the oxidoreductase DsbA (cf. lane 5–6 and 11–
12, Additional file 3: Figure S3B), which is required for the
formation of potentially obstructing disulfide bonded loops
[35], arguing that mainly other structural restraints prevent
secretion.
In an effort to solve this problem, we considered the
structure of Ag85B [34] to split it in Ag85B[N] (residues
1–126) and Ag85B[C] (residues 118–285) domains.
Ag85B[N] and Ag85B[C] were used to replace domains d1
and d2 using the strategy that has been described above
for ESAT6. Both fragments appeared fully compatible
with translocation across the cell envelope when inserted
individually into the Hbp passenger domain, as judged
by the emergence of cleaved passenger and β-domain
species upon expression of the corresponding Hbp de-
rivatives in E. coli MC1061 (lanes 3–6, Additional file 4:
Figure S4). Remarkably, in contrast to Ag85B[N] and ESAT6
[15], fusion to Ag85B[C] affected release of the Hbp pas-
senger into the culture medium (lane 5, Additional file 4:
Figure S4). It should be noted that the mechanism ofFigure 2 Secretion of multiple antigens fused to the Hbp autotranspo
the equivalent of 0.03 OD660 units cells (c) and corresponding culture med
(A) Expression and secretion of Hbp, Hbp-Ag85B[N+C] and Hbp-Ag85B[C+N]. (B
and Hbp-Ag85B[C+N]-ESAT6-RV2660c. (C) Samples described under B were ana
passenger (>) and β-domain (β) are indicated. Molecular weight markers (kDapassenger release, or rather retention at the OM, is un-
known. Apparently, this process can vary depending on
the nature of the inserted heterologous sequences.
The observed extracellular expression of Ag85B[N] and
Ag85B[C] encouraged us to combine the two fragments
in one Hbp carrier fusing Ag85B[N] at d1 and Ag85B[C] at
d2 (Hbp-Ag85B[N+C]) and vice versa (Hbp-Ag85B[C+N];
Additional file 2: Figure S2). The two split Ag85B-Hbp
versions were indeed expressed and processed, although
release into the medium was affected compared to wild-
type Hbp (Figure 2A, cf. lanes 1–2 and 3–6), similar to
Hbp only carrying Ag85B[C] (lane 5, Additional file 4:
Figure S4). Surprisingly, the positioning of the Ag85B
domains in Hbp influenced the efficiency of transport
with Hbp-Ag85B[C+N] being more proficient (Figure 2A,
cf. lanes 3 and 5). Importantly, the cleaved chimeric
passengers were intact as judged by their apparent mo-
lecular mass (Figure 2A) and reaction with monoclonal
antibodies against the Ag85B[C] moiety (Figure 2C, lane
3). Furthermore, they were fully accessible to Proteinase
K, indicating translocation across the OM (Additional
file 5: Figure S5A). These data demonstrate efficient
simultaneous secretion of Ag85B[C] and Ag85B[N] fused
to one Hbp molecule replacing side domains d1 and
d2, respectively.
Secretion and display of multiple mycobacterial antigens
To further explore the heterologous secretion capacity,
we added a second (ESAT6), and a third (Rv2660c) [28]rter. (A-B) Hbp constructs were expressed in E. coli MC1061 and
ium (m) samples was analyzed by SDS-PAGE and Coomassie staining.
) Expression and secretion of Hbp, Hbp-Ag85B[C+N], Hbp-Ag85B[C+N]-ESAT6
lyzed by immunoblotting using the antibodies indicated. Cleaved Hbp
) are shown at the left side of the panels.
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chimera. ESAT6 was inserted in d4 (Additional file 6:
Figure S6; Additional file 2: Figure S2) and d5 was substituted
by Rv2660c (Additional file 2: Figure S2). Both positions
were shown to be permissive with respect to the insertion
of heterologous sequences (Additional file 6: Figure S6)
[15]. The resulting 119 kDa Hbp-Ag85B[C+N]-ESAT6
and 125 kDa Hbp-Ag85B[C+N]-ESAT6-Rv2660c passen-
gers were efficiently transported to the cell surface, and
cleaved from their cognate β-domain as judged by their ap-
parent molecular mass and the presence of corresponding
amounts of cleaved 28 kDa β-domain in the cell samples
(Figure 2B, lanes 5–8; Figure 2C, lanes 5 and 7). Similar to
Hbp-Ag85B[C] (lane 5; Additional file 4: Figure S4) and
Hbp-Ag85B[C+N] (Figure 2B, lanes 3–4), the passengers
were not released to the medium (Figure 2B, lanes 5–8;
Figure 2C, lanes 5 and 7). However, their sensitivity to
externally added Proteinase K confirmed proper trans-
location across the OM (Additional file 5: Figure S5). The
presence of Ag85B[C], ESAT6 and Rv2660c in the chimeric
protein was demonstrated by immunoblotting confirm-
ing that the translocated chimeric passengers were intact
(Figure 2C). Although substantial amounts of translocated
material were observed for all constructs, increasing the
number of insertions came at the cost of a gradually lower
expression level (Figure 2B). Most likely, the cumulative
complexity introduced by the additional insertion of
ESAT6 and Rv2660c caused impaired secretion and partial
degradation by DegP in the periplasm [35]. Nevertheless,
the data clearly show that the Hbp passenger can function
as a carrier for efficient secretion of multiple antigens into
the extracellular environment.
To enable cell surface exposure of antigens rather than
release into the extracellular milieu, we previously con-
structed a ‘display’ version of the Hbp platform (HbpD)
[15] by disrupting the proteolytic cleavage site between
the passenger and the β-domain [36]. To test simultan-
eous display of multiple antigenic proteins, we created the
non-cleaved Hbp-antigen chimeras HbpD-Ag85B[C+N],
HbpD-Ag85B[C+N]-ESAT6 and HbpD-Ag85B[C+N]-ESAT6-
Rv2660c (Additional file 2: Figure S2). Expression of
these constructs was initially analyzed by SDS-PAGE and
Coomassie staining (Figure 3A). As expected when the
β-domain is not cleaved, the chimeras were detected in
the cell fraction with a ~30 kDa increase in apparent
molecular mass compared to their cleaved counterparts
(cf. Figure 3A and 2B). The presence of the β-domain as
well as the Ag85B, ESAT6 and Rv2660c antigens in the re-
spective passenger domains was verified by immunoblot-
ting (Figure 3B). To examine surface exposure of the Hbp
passenger and the fused antigens, intact cells were ana-
lyzed by immuno-EM using antibodies against the Hbp
carrier or the individual antigens (Figure 3C). For all chi-
meras, clear, dispersed surface labeling was observed usinganti-Hbp, demonstrating surface exposure of the respect-
ive Hbp passenger domains. Incubation with antibodies
against Ag85B[C], ESAT6 or Rv2660c further confirmed
display of all antigens at the cell surface (Figure 3C). As a
control, cells carrying an empty vector (EV) (Figure 3C)
or cells expressing a secretion-incompetent mutant of
Hbp (data not shown) were not labeled with any of
the antibodies tested. Of note, Hbp constructs lacking
the native domain d2 are poorly recognized by anti-Hbp
[15], whereas the monoclonal anti-Ag85B[C] recognizes
only a small single epitope of Ag85B [37]. This may
explain the relatively poor labeling of HbpD-Ag85B[C+N],
HbpD-Ag85B[C+N]-ESAT6 and HbpD-Ag85B[C+N]-ESAT6-
Rv2660c expressing cells using these antibodies.
Taken together, using the Hbp platform, efficient and
simultaneous extracellular transport was achieved of four
heterologous polypeptides, representing three complete
mycobacterial antigens.
Secretion and display of multiple mycobacterial antigens
by attenuated Salmonella Typhimurium
Attenuated derivatives of Salmonella enterica have been
proposed as vehicles for the mucosal delivery of heterol-
ogous antigens and as a basis for multivalent vaccines [1].
We previously demonstrated Hbp-mediated secretion and
display of a single antigen (ESAT6) by the attenuated
S. Typhimurium SL3261 vaccine strain [15] that has been
used for mucosal immunisation in numerous in vivo stud-
ies [1]. To test Hbp as a platform for the development of
multivalent live vaccines, the secretion and display of the
antigens ESAT6, Ag85B and Rv2660c was analyzed using
S. Typhimurium SL3261 as expression host (Figure 4).
To achieve stable expression, single copies of the genes
encoding either Hbp-Ag85B[C+N]-ESAT6-Rv2660c or HbpD-
Ag85B[C+N]-ESAT6-Rv2660c were integrated into the gen-
ome of SL3261. Expression of the genes was controlled by
a lacUV5 promoter, which is constitutively active in
Salmonella since this bacterium does not have a lac
operon and thus does not produce the LacI repressor.
Substantial amounts of Hbp passenger containing the
three antigens were detected in the culture medium
indicating efficient expression, OM translocation and
release of Hbp-Ag85B[C+N]-ESAT6-Rv2660c in Salmon-
ella (Figure 4A, lane 4). Immunoblotting using antibodies
specific for Hbp or any of the three mycobacterial antigens
confirmed that the chimera was intact (Figure 4B). Of
note, when the same Hbp variant was expressed in E. coli
MC1061, the passenger was almost completely retained at
the cell surface (Figure 2B), indicating that the thus far un-
clear mechanism of passenger release can vary depending
on the bacterial expression host used. Conceivably, the
smooth and rough lipopolysaccharide phenotypes dis-
played by S. Typhimurium SL3261 [38] and E. coli K-12
strain MC1061 [39], respectively, result in differential
Figure 3 (See legend on next page.)
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Figure 3 Display of multiple antigens fused to one Hbp carrier in E. coli. (A-B) Display of antigens fused to the passenger of the non-cleaved
HbpD. E. coli MC1061 cells expressing either Hbp(Δβ-cleav), HbpD-Ag85B[C+N], HbpD-Ag85B[C+N]-ESAT6 or HbpD-Ag85B[C+N]-ESAT6-Rv2660c were
analyzed as described in the legend to Figure 2 by Coomassie staining (A) and immunoblotting (B). Non-cleaved Hbp species (*) are indicated.
(C) Cells described under A and cells carrying the empty vector (EV) pEH3 were fixed and analyzed by immuno-EM using the indicated
antibodies as described before [15]. Scale bar: 100 nm.
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senger with the bacterial cell surface.
The display variant HbpD-Ag85B[C+N]-ESAT6-Rv2660c
was detected in the cell fraction of Salmonella (Figure 4A,
lane 5) in an intact form (Figure 4B). To confirm surface
exposure, intact cells expressing the construct were
treated with Proteinase K to digest extracellular proteins
(Figure 4C). Clearly, HbpD-Ag85B[C+N]-ESAT6-Rv2660c
was specifically degraded. Maintenance of cell integ-
rity during the procedure was demonstrated by the in-
accessibility of the periplasmic chaperone SurA towards
Proteinase K (Figure 4D, cf. lanes 3 and 4). Taken together,
the Hbp platform allows the efficient extracellular expres-
sion of multiple mycobacterial antigens by an attenuated
Salmonella vaccine strain.
Display of antigenic sequences from C. trachomatis and
the influenza virus
We demonstrated effective secretion and display of anti-
gens derived from M. tuberculosis. To investigate the ver-
satility of the Hbp system we tested its compatibility with
antigenic sequences from two other pathogens: the bacter-
ium C. trachomatis and the influenza A virus.
First we analyzed the Hbp-mediated surface display of
sizeable fragments of the immunodominant chlamydial
outer membrane protein MOMP (Figure 5A) [40]. We se-
lected a 9 kDa fragment, MOMPIV, which corresponds to
the predicted surface exposed variable sequence 4 (VS4)
region, a cluster of T-cell epitopes located in a predicted
periplasmic loop, and a connecting transmembrane
β-strand [40]. The MOMPIV sequence was fused to the
passenger of HbpD, replacing domain d1. In addition, a
3.4 kDa fragment MOMPII that represents the surface-
exposed VS2 region and an adjacent T-cell epitope [40]
was inserted into the same HbpD molecule at the position
of domain d2 (Additional file 2: Figure S2). Upon produc-
tion from vector pEH3, the resulting HbpD-MOMPIV-
MOMPII fusion was expressed with a remarkable effi-
ciency at the surface of S. Typhimurium SL3261, almost
on par with the non-antigen-carrying control HbpD(Δd1)
[15] (Figure 5A, cf. lanes 1 and 3). HbpD-MOMPIV-
MOMPII was detected by antibodies against the Hbp
β-domain or MOMP (Figure 5B, lanes 3 and 7) and dis-
played a ~10 kDa increase in molecular weight com-
pared to HbpD(Δd1) (Figure 5A, cf. lanes 1 and 3),
corroborating the integrity of the construct. Confirm-
ing surface localization, the construct appearedaccessible to Proteinase K added to intact cells (Fig-
ure 5A, lane 4; Figure 5B, lanes 4 and 8) whereas the
intracellular Proteinase K-sensitive domain of OmpA [41]
remained inaccessible under these conditions (Figure 5B,
lane 8).
As an alternative to bacterial antigens, three immuno-
genic sequences from the influenza A virus were simul-
taneously fused to HbpD. In this construct, side domain
d1 was replaced by a 6.5 kDa fragment of the surface ex-
posed hemagglutinin (HA) 2 protein of influenza A/PR/
8/34 that forms a long conserved α–helix in the stem re-
gion of the HA [42]. Next, domain d2 was substituted by
the first 23 aa of the conserved matrix protein 2 (M2),
which constitute the so-called M2 ectodomain (M2e) that
is normally exposed at the surface of the influenza virus
particle and of infected host cells [43]. Finally, a third se-
quence encoding a string of immunodominant cytotoxic
T cell epitopes [44,45] was inserted into domain d4. This
12 kDa sequence comprised segments of the internal nu-
cleoprotein (NP), the polymerase acidic protein (PA) and
matrix protein 1 (M1) from A/PR/8/34, interspaced by
short flexible glycine/serine linkers. Upon plasmid-based
production in S. Typhimurium SL3261, the HbpD-HA2stem-
M2e-NP/PA/M1 chimera (Additional file 2: Figure S2)
was efficiently expressed at a Coomassie-detectable level
(Figure 5C, lane 3) and properly recognized by antibodies
against M2e and the β-domain of Hbp (Figure 5D, lanes 3
and 7). Furthermore, in contrast to OmpA (Figure 5D,
lane 8), the construct appeared sensitive to incubation
with Proteinase K (Figure 5C, lanes 4; Figure 5D, lanes 4
and 8), confirming its localization at the cell surface.
In conclusion, the Hbp platform was successfully used
to achieve high-density display of multiple antigenic
fragments of bacterial and viral origin at the surface of
an attenuated Salmonella vaccine strain. These data
highlight the potential of Hbp as a versatile generic anti-
gen display platform for the development of multivalent
bacterial vector vaccines.
Discussion
To achieve surface display, antigen fragments have been
translationally fused to surface-exposed proteins like in-
tegral outer membrane proteins, ice-nucleation protein
and fimbriae [46], whereas secretion has been accom-
plished upon fusion to components of the type I-III secre-
tion pathways [47]. Unfortunately, the size and complexity
of the antigens that can be handled by these systems are
Figure 4 Secretion and display of antigens by attenuated Salmonella Typhimurium. (A-B) Secretion and display of antigens fused to the
Hbp passenger. S. Typhimurium SL3261 (unlabeled) and derivatives expressing Hbp-Ag85B[C+N]-ESAT6-Rv2660c or HbpD-Ag85B[C+N]-ESAT6-Rv2660c
were analyzed by SDS-PAGE and Coomassie staining (A) or immunoblotting using the indicated antibodies (B). The equivalent of 0.03 OD660 units
cells (c) and corresponding culture medium (m) samples was analyzed. (C-D) Exposure of antigens at the S. Typhimurium cell surface. (C) SL3261 cells
(lane 1–2) and derivatives expressing HbpD-Ag85B[C+N]-ESAT6-Rv2660c from A were treated with Proteinase K (+ pk) or mock-treated (− pk).
(D) Samples described under C were analyzed by immunoblotting. Cell integrity during the procedure was demonstrated by showing the
inaccessibility of the periplasmic chaperone SurA towards Proteinase K using anti-SurA (cf. lanes 1, 3, 5 and 2, 4, 6, resp.). Cleaved Hbp
passenger (>), non-cleaved Hbp species (*), the cleaved β-domain (β) and Proteinase K (pk) are indicated. An unrelated protein that cross-reacts
with the Hbp β-domain antiserum is indicated (x). A proteolytic fragment of HbpD-Ag85B[C+N]-ESAT6-Rv2660c is indicated (f). Molecular weight markers
(kDa) are shown at the left side of the panels.
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pathway is better equipped to this task [4,10,11]. However,
thus far, efforts to exploit the system for the extracellular
expression of antigens in vaccine strains such as attenu-
ated Salmonella were restricted to single antigens or mul-
tiple small epitopes and yielded limited success [12-24].
Here, we modified the autotransporter Hbp into a multi-
valent vaccine antigen carrier that can display at least four
antigenic sequences from M. tuberculosis with a combined
mass of ~50 kDa at the cell surface of E. coli (Figure 3)and attenuated S. Typhimurium (Figure 4). Notably,
successful display of this complex chimera could be
visualized upon analysis of whole cell material on
Coomassie-stained gels (Figure 3) equaling at least ~1.4
× 104 molecules per cell (data not shown) without
optimization of expression conditions. In addition, high-
density multivalent display was observed of sizeable anti-
genic fragments from two other pathogens, Chlamydia
trachomatis and the influenza A virus, emphasizing the
flexibility of the Hbp system.
Figure 5 Display of antigenic fragments from C. trachomatis and the influenza A virus by attenuated Salmonella. (A) S. Typhimurium
SL3261 cells expressing HbpD(Δd1) or HbpD-MOMPIV-MOMPII. Cells were treated with Proteinase K (+ pk) or mock-treated (− pk) before analysis
by Coomassie stained SDS-PAGE. (B) Cells from A were analyzed by immunoblotting using antibodies against the Hbp β-domain, chlamydial
MOMP or OmpA as indicated. (C) S. Typhimurium SL3261 cells expressing HbpD(Δd1) or HbpD-HA2stem-M2e-NP/PA/M1. Cells were as described
under A. (D) Cells from C were analyzed by immunoblotting using antibodies against the Hbp β-domain, influenza M2e and OmpA as indicated.
Non-cleaved Hbp species (*), proteolytic fragments of the Hbp-derivatives (f) and a truncate of HbpD-HA2stem-M2e-NP/PA/M1 (>) are indicated.
Molecular weight markers (kDa) are shown at the left side of the panels.
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fusion protein was previously shown to yield better
immune responses and protection against M. tubercu-
losis than a cocktail of the individual antigens,
highlighting the benefit of combining multiple anti-
gens in a single Hbp carrier molecule [48,49]. Also,
the production of live vaccines consisting of a sole strain
exposing multiple antigens is more cost-efficient thanformulations comprising a mixture of strains expressing
single antigens. Moreover, approaches involving the ex-
pression of multiple Hbp-antigen constructs in parallel
within a single host may lead to instability at the genetic
level due homologous recombination events between the
Hbp coding sequences, arguing for the use of a singular
translocation system to achieve multivalent antigen
display.
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molecule that protrude from the β-stem core in the na-
tive structure. We have previously shown that this re-
placement strategy is critical to maintain the stability of
Hbp chimeras upon exposure to the extracellular envir-
onment [15]. Furthermore, compared to fusion to trun-
cated autotransporters [10], the intact ~100 Å long
β-stem [25] offers the advantage of optimal presentation
of antigens at some distance from the cell surface. Although
not addressed in this study, the cross-β structure exhibited
by the stem of the Hbp passenger has also been suggested
to have immunostimulatory properties that are considered
beneficial for vaccination purposes [50]. Importantly, re-
placement of the passenger side-domains by heterologous
sequences removes the functional regions of the autotran-
sporter [25,51] with their associated potential toxicity and
makes the Hbp platform safe to use for vaccination.
Despite very efficient surface exposure overall, consider-
able differences in display efficiencies were observed.
Whereas HbpD-MOMPIV-MOMPII was exported at levels
similar to wild-type Hbp, the HbpD-Ag85B[C+N]-ESAT6
and HbpD-Ag85B[C+N]-ESAT6-Rv2660c chimeras ap-
peared at the cell surface with reduced efficiencies. One
critical parameter seems to be the number of inserted
antigens, which appears inversely correlated to the export
efficiency of Hbp (Figures 2 and 3). Furthermore, the na-
ture of individual fused sequences may influence the bio-
genesis of Hbp fusion proteins for example by interfering
with proper formation of the β-helical stem [26] or ham-
pering transport via the narrow outer membrane trans-
location machinery [9]. In the latter case, fusion partners
with strong folding potential may compromise transloca-
tion, as was observed for full-length Ag85B (Additional
file 3: Figure S3). Recent evidence suggests that fused pro-
teins carrying positively charged amino acid stretches
affect autotransporter secretion [52]. However, none of
the sequences that were inserted into Hbp contained simi-
lar positively charged stretches, so charge variation does
not explain the differences in display efficiency observed
in our study. It should be mentioned that heterologous
sequences with a strongly hydrophobic character are not
compatible with the Hbp system (data not shown), prob-
ably because they cause stalling of the fusion protein
already at the level of the Sec-translocon in the inner
membrane [53]. Bioinformatics analysis revealed a sig-
nificant degree of hydrophobicity in Ag85B[C] (data not
shown), which may explain the reduced secretion and
display efficiencies in constructs carrying this antigen.
Interestingly, rather than their features per se, the location
of individual sequences in the Hbp passenger also plays a
role as fusion proteins carrying Ag85B[N] and Ag85B[C] at
the d1 and d2 positions, respectively, was less efficiently se-
creted than its counterpart carrying these domains at the
inverse positions, d2 and d1 (Figure 2A).In line with previous work [9,35], the complex and bulky
Ag85B [34] appeared incompatible with Hbp-mediated se-
cretion as a whole and had to be fused as a split antigen in
order to sustain secretion via the Hbp pathway. Remark-
ably, it was recently reported that intact Ag85B can be se-
creted when fused to a strongly truncated passenger of
Pet, a SPATE autotransporter like Hbp [22]. Although in
the concerning paper the efficiency of secretion is hard to
judge, it is possible that fusion to an intact Hbp passenger
domain slows down the secretion kinetics, which could
allow Ag85B to fold into a translocation-incompetent con-
formation. On the other hand, the disparate results may
be due to subtle differences in experimental conditions,
which can have a significant influence on the secretion of
folded proteins via the autotransporter pathway [54].
By using flexible flanking glycine/serine spacer sequences,
antigens were fused to the Hbp β-stem in a context that
allows their independent movement and folding. It should
be noted that native folding of immunizing antigens seems
less important for diseases like tuberculosis (TB) that re-
quire vaccines that induce cellular immunity [55], which
relies on the presentation of extensively processed anti-
gens to the immune system [56]. However, antigen fold-
ing may be a critical parameter for eliciting humoral
responses to preserve conformational epitopes [57]. In
the present work we did not address the conformation of
antigens upon fusion to Hbp per se but we previously
observed Ca2+ dependent secretion inhibition of an
Hbp-calmodulin fusion protein, indicative of functional
folding of calmodulin when fused to Hbp [35]. Further-
more, preliminary data have shown that both monomeric
streptavidin [58] and the ZZ domain of protein A from
Staphylococcus aureus [59] are fully functional in the
binding of their ligands biotin and immunoglobulins, re-
spectively, when displayed at the E. coli cell surface using
Hbp (data not shown). These data demonstrate proper
folding of heterologous proteins upon fusion to the Hbp
β-stem.
The causative agents of TB, chlamydia and influenza in-
fect individuals via mucosal tissues. Various studies sug-
gest that antigen delivery via the same mucosal routes
may elicit local immunity to enhance protection against
infection [60]. Attenuated Salmonella is regarded as a
promising antigen delivery vehicle to meet this purpose as
it efficiently invades mucosa-associated lymphoid tissues
and provokes strong mucosal as well as systemic immune
responses [1]. Importantly, secretion and surface display
of antigens has been shown to yield more potent immune
responses as compared to expression in the cytoplasm of
the vaccine strain [2,3]. Interestingly, extracellular antigen
expression induced not only CD4+ T cells, as generally ob-
served with antigen delivery by phagocytosed bacteria like
Salmonella, but also CD8+ T cells [2], similar to the deliv-
ery of heterologous antigens directly to the cytosol via
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We have used our Hbp platform to create a live attenu-
ated Salmonella strain that displays all constituents of
the recently described multistage tuberculosis subunit
vaccine H56 (ESAT6-Ag85B-Rv2660c) at the cell surface
[28] (Figure 4). In the same context we achieved display of
two fragments of the highly immunogenic MOMP that
are known to contain important B and T cell epitopes and
could form the basis for a vaccine against chlamydial
disease [40]. Moreover, two conserved protein fragments
plus a string of CD8+ T cell epitopes from the influenza
virus, representing promising influenza vaccine targets
[43-45,62], were expressed at the surface of Salmonella.
Whether Hbp-mediated surface expression of abovemen-
tioned antigens on live cells or derived outer membrane
vesicles and bacterial ghosts will lead to successful vaccin-
ation strategies against TB, chlamydia and influenza will
be investigated in future challenge studies.Conclusions
In the present work we describe the engineering of the
autotransporter Hbp into a platform for the secretion or
display of multiple recombinant antigens by Gram-negative
bacteria. To highlight the capacity and versatility of the
platform we demonstrate efficient translocation of up to
four sizeable antigenic sequences from various pathogenic
organisms (M. tuberculosis, C. trachomatis and Influenza
A virus) per Hbp carrier molecule in E. coli and an attenuated
Salmonella vaccine strain. The Hbp platform can be used
for the generation of multivalent recombinant bacterial
live vaccines but also for derived non-living vaccines based
on outer membrane vesicles or bacterial ghosts.Methods
Strains and culturing conditions
Strain MC1061 [63] was routinely used for expression of
Hbp and its derivatives in E. coli. Where indicated, E.
coli strains MC1061degP::S210A [64,65], DHB4 [66],
DHB4dsbA::kan (DHBA) [66] or TOP10F’ (Invitrogen)
were used. Plasmid-borne expression of Hbp deriva-
tives in S. Typhimurium was carried out using strain
SL3261 [67]. To construct S. Typhymurium SL3261 strains
expressing either Hbp-Ag85B[C+N]-ESAT6-Rv2660c or
HbpD-Ag85B[C+N]-ESAT6-Rv2660c, the respective coding
sequences and an upstream lacUV5 promoter region were
inserted into the chromosome by allelic exchange through
double cross-over homologous recombination replacing
the malE and malK promotor regions. This was done as
described [15], except that pHbp-Ag85B[C+N]-ESAT6-
Rv2660c and pHbpD-Ag85B[C+N]-ESAT6-Rv2660c (see under
Plasmid construction) were used as templates to PCR-amplify
the sequences for cloning into the suicide vector.Cells were grown at 37°C in LB medium containing 0.2%
glucose. The antibiotics chloramphenicol (30 μg/ml) and
streptomycin (25 μg/ml) were added where appropriate.
Reagents and sera
Restriction enzymes, Alkaline phosphatase and DNA lig-
ase (Rapid DNA Dephos & Ligation Kit), Lumi-light
Western blotting substrate and Proteinase K (recombin-
ant, PCR grade) were purchased from Roche Applied
Science, Phusion DNA polymerase from Finnzymes, and
electron microscopy (EM) grade paraformaldehyde and
glutaraldehyde from Electron Microscopy Sciences. The
polyclonal antisera against the Hbp passenger (J40) and
β-domain (SN477) [68,69], as well as the monoclonal anti-
bodies against ESAT6 (HYB 76–8) and Ag85B[C] (TD17)
[37,70] have been described previously. The rabbit poly-
clonal antisera against OmpA and C. trachomatis D/UW-
3/CX MOMP, as well as the rat polyclonal antiserum
against Rv2660c were from our own lab collection. The
rabbit polyclonal antiserum against SurA was a gift
from T. Silhavy (Princeton University, USA) and the
mouse monoclonal antibody against M2e was a gift from
X. Saelens (University of Ghent, Belgium).
Plasmid construction
All plasmids used are derivatives of pEH3 [71]. pHbp(d4in)
was created upon substitution of the coding sequence for
residues 708–712 of the passenger of pEH3-Hbp(ΔBamHI)
[15] by a Gly/Ser encoding linker sequence containing SacI
and BamHI restriction sites using overlap-extension PCR.
The primers used were Hbp(d4in) fw and Hbp(d4in) rv,
yielding pHbp(d4in).
To insert the coding sequence for ESAT6 into pHbp
(d4in), an E. coli-codon-usage-optimized synthetic gene
of M. tuberculosis gene esxA was constructed by Baseclear
B.V. The synthetic gene was flanked by 5′-gagctcc-3′ and
5′-ggatcc-3′ sequences at the 5′ and 3′ site, respectively,
allowing in-frame insertion into the hbp ORF using the
SacI/BamHI restriction sites, giving rise to pHbp(d4ins)-
ESAT6.
Plasmid pHbp-Ag85B was constructed by amplifying
the Ag85B-encoding gene fbpA with flanking SacI/
BamHI restriction sites by PCR using M. tuberculosis
H37Rv genomic DNA as a template. The primers used
were Cas/Ag85B fw and Cas/Ag85B rv. The PCR frag-
ment was cloned into pHbp(Δd1) [15] using the SacI/
BamHI restriction sites, resulting in pHbp-Ag85B. To
construct pHbp-Ag85B[N+C] and pHbp-Ag85B[C+N], frag-
ments of fbpA encoding Ag85B[N] and Ag85B[C] were
generated with flanking SacI/BamH sites using M. tuber-
culosis H37Rv genomic DNA as a template. For Ag85B[N],
the primers used were Cas/Ag85B fw and Cas/Ag85B
(S126) rv. The resulting PCR fragment was cloned into
pHbp(Δd1) and pHbp(Δd2) [15] using the SacI/BamHI
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(Δd2)-Ag85B[N], respectively. For Ag85B[C] the primers
used were Cas/Ag85B(T118) fw and Cas/Ag85B rv. The
resulting PCR fragment was inserted into pHbp(Δd1) and
pHbp(Δd2) [15] using the SacI/BamHI restriction sites,
creating pHbp(Δd1)-Ag85B[C] and pHbp(Δd2)-Ag85B[C],
respectively. Subsequently, the XbaI/NdeI fragment of
pHbp(Δd2)-Ag85B[C] was substituted by the XbaI/NdeI
fragment of pHbp(Δd1)-Ag85B[N], yielding pHbp-Ag85B[N+C],
and the XbaI/NdeI fragment of pHbp(Δd2)-Ag85B[N] was
substituted by the XbaI/NdeI fragment of pHbp(Δd1)-
Ag85B[C], giving pHbp-Ag85B[C+N].
To create a plasmid expressing Hbp fused to both Ag85B
and ESAT6, the NsiI/KpnI fragment of pHbp-Ag85B[C+N]
was substituted by that of pHbp(d4in)-ESAT6, creating
pHbp-Ag85B[C+N]-ESAT6. To make a version of this plas-
mid additionally expressing Rv2660c, plasmid pHbp(Δd5)-
Rv2660c was created first. To this end, Rv2660c with
flanking SacI/BamHI sites was amplified by PCR using
M. tuberculosis H37Rv genomic DNA as a template. The
primers used were Cas/Rv2660c fw and Cas/Rv2660c rv.
The PCR product was cloned into pHbp(Δd5) [15] using
the SacI/BamHI sites, creating pHbp(Δd5)-Rv2660c. Subse-
quently, the BstZ17i/KpnI fragment of pHbp-Ag85B[C+N]-
ESAT6 was substituted by that of pHbp(Δd5)-Rv2660c,
giving pHbp-Ag85B[C+N]-ESAT6-Rv2660c.
To construct display versions of pHbp-Ag85B[C+N],
pHbp-Ag85B[C+N]-ESAT6 and pHbp-Ag85B[C+N]-ESAT6-
Rv2660c, the XbaI/KpnI fragments of these plasmids were
substituted for that of pEH3-HbpD(ΔBamHI) [15]. This
resulted in pHbpD-Ag85B[C+N], pHbpD-Ag85B[C+N]-ESAT6
and pHbpD-Ag85B[C+N]-ESAT6-Rv2660c, respectively.
To create plasmids for expression of epitopes from C.
trachomatis MOMP, two E. coli-codon-optimized synthetic
DNA fragments were ordered from Life Technologies that
coded for sequences including and flanking the VS2
(‘MOMPII’; residues 155–190) and VS4 loops (‘MOMPIV’;
residues 266–350) of MOMP from C. trachomatis D/









Cas/Rv2660c rvof pHbp derivatives by SacI/BamHI digestion, the DNA
fragments were synthesized with flanking 5′-gagctcc-3′
and 5′-ggatcc-3′ sequences at the 5′ and 3′ site, respect-
ively. The synthetic sequences were cloned into pEH3-
Hbp(Δd2) and pEH3-Hbp(Δd1), respectively [15], yielding
pHbp(Δd2)-MOMPII and pHbp(Δd1)-MOMPIV. To cre-
ate a construct for the expression of Hbp fused to both
MOMP fragments, the NdeI/NsiI fragment of pHbp(Δd1)-
MOMPIV was substituted by that of pHbp(Δd2)-MOMPII
resulting in pHbp-MOMPIV-MOMPII. To construct a
display version of this construct, the KpnI/EcoRI fragment of
pHbp-MOMPIV-MOMPII was substituted by that of pEH3-
HbpD(ΔBamHI), yielding pHbpD-MOMPIV-MOMPII.
Synthetic E. coli-codon-optimized DNA fragments en-
coding the HA2 stem region of the HA protein of the in-
fluenza isolate A/PR/8/34 (H1N1) (aa 76–130) [72], and
the universally conserved ectodomain of the influenza M2
protein (aa 1–23) [43] were ordered from Life Technolo-
gies. An additional E. coli-codon-optimized synthetic
DNA sequence was ordered, in which fragments coding
for residues 356–401 of the NP, 214–243 of the PA and
48–76 of the M1 proteins of influenza A/PR/8/34, spaced
by Gly/Ser-encoding linker sequences, were assembled.
The three fragments, ‘HA2stem’, ‘M2e’ and ‘NP/PA/M1’
were flanked by 5′-gagctcc-3′ and 5′-ggatcc-3′ sequences
at the 5′ and 3′ site, respectively, allowing insertion into
the hbp ORF of and pHbpD derivatives by SacI/BamHI
digestion. In this way, pHbpD(Δd1)-HA2stem, pHbp
(Δd2)-M2e and pHbp(Δd4)-NP/PA/M1 were created. To
construct a plasmid for the expression of all three influ-
enza sequences, the NsiI/KpnI fragment of pHbp(Δd2)-
M2e was first substituted by that of pHbp(Δd4)-NP/PA/
M1, resulting in pHbp-M2e-NP/PA/M1. Subsequently,
the NdeI/KpnI fragment of this plasmid was substituted
for that of pHbpD(Δd1)-HA2stem, resulting in plasmid
pHbpD-HA2stem-M2e-NP/PA/M1.
Nucleotide sequences of all constructs were confirmed
by semi-automated DNA sequencing. Primer sequences
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Cells were resuspended in ice-cold reaction buffer (50 mM
Tris HCl, pH 7.4, 1 mM CaCl2). Subsequently, Proteinase
K was added to a concentration of 100 μg/ml to one half
of the suspension, whereas the other half was mock-
treated, and the suspensions were incubated at 37°C
for 1 h. Thereafter, phenylmethanesulfonyl fluoride (0.1 mM)
was added and the suspensions were incubated on ice for
10 min. Samples were then TCA precipitated and ana-
lyzed by SDS-PAGE and Coomassie staining or immuno-
blotting as indicated.
General protein expression and analysis
For analysis of plasmid-borne expression of Hbp (deriva-
tives), cultures were grown to early log-phase (OD660 ≈ 0.3)
before protein production was induced by the addition of
1 mM IPTG. Growth was continued for 2 h, after which
samples were withdrawn from the cultures for further
analysis. For analysis of genome-based expression of Hbp-
derivatives, Salmonella cultures were grown to mid-log
phase before withdrawal of samples. In all cases, cul-
ture samples were separated into cells and spent medium
by low speed centrifugation, and analyzed by SDS-PAGE
followed by Coomassie (G-250) staining or immunoblotting.
Cells were resuspended in SDS-sample buffer (125 mM
Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 0.02% bromo-
phenol blue, 100 mM dithiothreitol) directly whereas medium
samples were first TCA-precipitated.
Additional files
Additional file 1: Figure S1. Side domains of the Hbp passenger
domain.
Additional file 2: Figure S2. Schematic representation of Hbp
derivatives used in the study.
Additional file 3: Figure S3. Expression of Hbp-Ag85B in degP- and
dsbA-mutant strains.
Additional file 4: Figure S4. Secretion of Ag85B[N] and Ag85B[C] upon
fusion to Hbp.
Additional file 5: Figure S5. Proteinase K accessibility of cleaved Hbp
passenger-antigen fusions at the cell surface.
Additional file 6: Figure S6. Secretion of ESAT6 inserted into d4.
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